Feed ARGX
AR

Argenx

ARGX · NASDAQ

$990.54 -1.40% (-$14.02)
1M +0.27%
Market Cap $61.6B
P/E Ratio 47.68x
Div. Yield -
ROE 18.91%

Bulios Fair Price

$990.96

0.0% upside

Trenutna cena

$990.54

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price se delnica ARGX trenutno trguje blizu svoje poštene vrednosti. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
5/9
Valuation
10 /100
Expensive
P/E 47.68x
P/FCF 72.96x
EV/EBITDA 44.39x
Growth
100 /100
Growing
Rev. growth 116.24%
Book val. growth 37.55%
EPS growth N/A
Profitability
100 /100
Strong
Gross margin 89.15%
FCF margin 20.33%
Net margin 31.11%
Quality
78 /100
Excellent
ROIC 14.45%
Asset turnover 0.48x
ROE 18.91%
Debt
100 /100
Low
Debt/Equity 0.01x
Net debt/EBITDA -2.60x
Current ratio 5.23x
Stability
18 /100
Unstable
Beta -0.02x
Profitable years 2
Rev. volatility 66.30%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ARGX
Online

O podjetju

Argenx SE is a biopharmaceutical company based in Belgium, focusing on the development and commercialization of innovative therapies for the treatment of autoimmune diseases and malignant tumors. The company specializes in the development of monoclonal antibodies and utilizes its technology platform for the discovery and development of new drug candidates. Argenx focuses on therapeutic areas such as immunology, hematology, and oncology, aiming to provide potential treatments for patients with severe diseases who have limited therapeutic options available. The company also collaborates with pharmaceutical partners on the development and commercialization of its products. Argenx SE could be suitable for investors seeking opportunities in the biotechnology and pharmaceutical industries, with an emphasis on innovative therapies for the treatment of serious diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Karen Massey

Employees

1,863

Headquarters

Amsterdam

Prihajajoči dogodki

04 MAR.

Earnings

Upcoming earnings report

170d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.